Lexeo Therapeutics, Inc. - LXEO

Sector: Healthcare · Industry: Biological Products, (No Diagnostic Substances)
Website: No information yet · Social: No information yet

Company profile

Powered by TradingView

Quarter snapshot

Latest / Compare
Q1 2026 · Q4 2025
Value (USD)
Total reported value ($000)
$498.7M
QoQ value delta ($000)
-$399M (-44.45%)
Implied price effect (QoQ)
-49.39%
Shares
Total shares
83,953,425
QoQ shares delta
+7,464,302 (+9.76%)
Total shares held by funds (by quarter)

Market chart (LXEO)

Powered by TradingView
Interactive chart by TradingView.

Top holders (Q1 2026)

Top 25 only Full list
Partial Q1 2026 data: 139 holders have filed so far. Prior holders are carried forward until their next 13F confirms a change.
Manager Value ($000) Shares % of 13F
VANGUARD GROUP INC 38,670 3,894,310 0.0%
Paradigm Biocapital Advisors LP 35,496 6,184,134 0.73%
BlackRock, Inc. 29,336 5,110,871 0.0%
Affinity Asset Advisors, LLC 28,988 5,050,211 1.5%
RA CAPITAL MANAGEMENT, L.P. 28,700 5,000,000 0.3%
JANUS HENDERSON GROUP PLC 28,510 4,976,429 0.01%
Vestal Point Capital, LP 25,686 4,475,000 0.72%
Frazier Life Sciences Management, L.P. 25,397 4,424,725 0.65%
CITADEL ADVISORS LLC 22,074 3,845,699 0.0%
ORBIMED ADVISORS LLC 20,678 3,602,450 0.41%
STATE STREET CORP 20,481 3,568,242 0.0%
VANGUARD CAPITAL MANAGEMENT LLC 17,260 3,007,093 0.0%
Woodline Partners LP 15,788 2,750,532 0.06%
GOLDMAN SACHS GROUP INC 11,192 1,949,885 0.0%
Avoro Capital Advisors LLC 10,762 1,875,000 0.11%
Point72 Asset Management, L.P. 9,645 1,680,449 0.01%
MILLENNIUM MANAGEMENT LLC 9,257 1,612,780 0.0%
BALYASNY ASSET MANAGEMENT L.P. 9,124 1,589,585 0.01%
GEODE CAPITAL MANAGEMENT, LLC 8,691 1,513,777 0.0%
ADAR1 Capital Management, LLC 8,422 1,467,350 0.5%
SUVRETTA CAPITAL MANAGEMENT, LLC 7,175 1,250,000 0.18%
683 Capital Management, LLC 6,888 1,200,000 0.36%
Nantahala Capital Management, LLC 6,888 1,200,000 0.25%
DIMENSIONAL FUND ADVISORS LP 6,331 1,103,584 0.0%
Octagon Capital Advisors LP 6,314 1,100,000 0.7%